Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 24, 2025
Subject: Top-line results from the 2-year primary analysis of the EVOKE and EVOKE+ Phase 3 trials evaluating oral semaglutide for early-stage symptomatic Alzheimer's disease.
Key Financial Metrics
This filing is a clinical trial announcement and does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Clinical Results
- Primary Outcome: The EVOKE and EVOKE+ trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression for oral semaglutide compared to placebo.
- Measurement: Efficacy was measured by the change in Clinical Dementia Rating – Sum of Boxes (CDR-SB) score from baseline to week 104.
- Biomarkers: While semaglutide improved Alzheimer's disease-related biomarkers in both trials, this did not translate into a delay of disease progression.
- Study Scope: The trials enrolled a total of 3,808 adults (aged 55-85) with mild cognitive impairment or mild dementia due to Alzheimer's disease.
- Safety: Semaglutide maintained a safe and well-tolerated profile consistent with previous trials in diabetes and obesity populations.
Outlook, Management Commentary, and Risks
- Management Commentary: Martin Holst Lange, Chief Scientific Officer, stated that despite a low likelihood of success, the company felt a responsibility to explore semaglutide's potential given the unmet need in Alzheimer's disease. He emphasized the rigorous methodology of the trials.
- Strategic Impact: The 1-year extension period in the EVOKE and EVOKE+ trials will be discontinued based on the efficacy results.
- Future Focus: Management reaffirmed that the extensive evidence base for semaglutide continues to support its benefits for type 2 diabetes, obesity, and related comorbidities.
- Upcoming Presentations: Topline results will be presented at the Clinical Trials in Alzheimer's Disease (CTAD) conference on December 3, 2025, with full results at the 2026 Alzheimer's and Parkinson's Diseases Conferences in March 2026.
Key Facts for Investor Verification
- Confirm the discontinuation of the EVOKE/EVOKE+ trial extension periods and any associated financial write-offs or R&D expense adjustments in future quarterly reports.
- Verify the continued performance and market share of core semaglutide products (Ozempic, Rybelsus, Wegovy) in diabetes and obesity indications, which remain unaffected by these results.
- Monitor upcoming presentations at the CTAD conference (Dec 3, 2025) and AD/PD conference (March 2026) for detailed safety and biomarker data.
- Assess the impact of this negative result on the company's broader pipeline valuation and R&D strategy for neurodegenerative diseases.